DEUTERIUM-ENRICHED AZTREONAM

1 . A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 17 are independently selected from H and D; and

the abundance of deuterium in R 1 -R 17 is at least 6%.

2 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 17 is selected from at least 6% , at least 12%, at least 18%, at least 24%, at least 29%, at least 35%, at least 41%, at least 47%, at least 53%, at least 59%, at least 65%, at least 71%, at least 76%, at least 82%, at least 88%, at least 94%, and 100%.

3 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 5 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

4 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 6 is selected from at least 100%.

5 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 7 -R 12 is selected from at least 17%, at least 33%, at least 50%, at least 67%, at least 83%, and 100%.

6 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 13 -R 17 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

7 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 1-5 of Table 1.

8 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 6-10 of Table 2.

9 . An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 17 are independently selected from H and D; and

the abundance of deuterium in R 1 -R 17 is at least 6%.

10 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 1 -R 17 is selected from at least 6% , at least 12%, at least 18%, at least 24%, at least 29%, at least 35%, at least 41%, at least 47%, at least 53%, at least 59%, at least 65%, at least 71%, at least 76%, at least 82%, at least 88%, at least 94%, and 100%.

11 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 1 -R 5 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

12 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 6 is selected from at least 100%.

13 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 7 -R 12 is selected from at least 17%, at least 33%, at least 50%, at least 67%, at least 83%, and 100%.

14 . An isolated deuterium-enriched compound of claim 9 , wherein the compound is selected from compounds 1-5 of Table 1.

15 . An isolated deuterium-enriched compound of claim 9 , wherein the compound is selected from compounds 6-10 of Table 2.

16 . A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 17 are independently selected from H and D; and

the abundance of deuterium in R 1 -R 17 is at least 6%.

17 . A mixture of deuterium-enriched compound of claim 16 , wherein the compound is selected from compounds 1-5 of Table 1.

18 . A mixture of deuterium-enriched compound of claim 16 , wherein the compound is selected from compounds 6-10 of Table 2.

19 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

20 . A method for treating a disease selected from infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and/or gynecologic infections comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.